Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes AMSTERDAM, August 17 - SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel
View HTML
Toggle Summary Versartis Presents Positive Preclinical Data on Two Product Candidates at ENDO 09
New Company Focusing on Extending Half-Life of Drugs for Metabolic and Endocrine Diseases
View HTML
Toggle Summary Versartis Publishes Preclinical Abstracts for Two Product Candidates at 2009 American Diabetes Association Scientific Sessions
New Company Focusing on Extending Half Life of Drugs for Metabolic and Endocrine Diseases
View HTML
Toggle Summary Versartis, Inc. Completes Series A Funding of $11 Million [€7.9 M] in a Joint Venture between Index Ventures and Amunix, Inc.
Versartis, Inc. Completes Series A Funding of $11 Million [€7.9 M] in a Joint Venture between Index Ventures and Amunix, Inc. Redwood City, CA – June 2, 2009 – Versartis, Inc. announced today that it has closed a Series A financing with an initial commitment of $11 million [€7.9 M] from Index
View HTML